General Information
Drug ID
DR00291
Drug Name
Cisplatin
Synonyms
(SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Abiplatin; Biocisplatinum; Briplatin; Cis-DDP; Cis-Diamminedichloroplatinum; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Cismaplat; Cisplatin (Chemotherapy); Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Peyrone's chloride; Peyrone's salt; Plastin; Platamine; Platidiam; Platinoxan; Randa; Trans-diamminedichloridoplatinum(II)
Drug Type
Small molecular drug
Indication Ovarian cancer [ICD11: 2C73] Approved [1]
Sarcomas [ICD11: 2C35] Approved [1]
Testicular cancer [ICD11: 2C80] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=441203"></iframe>
3D MOL 2D MOL
Formula
Cl2H6N2Pt+2
Canonical SMILES
N.N.Cl[Pt+2]Cl
InChI
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+4/p-2
InChIKey
BSJGASKRWFKGMV-UHFFFAOYSA-L
CAS Number
CAS 15663-27-1
Pharmaceutical Properties Molecular Weight 300.046 Topological Polar Surface Area 2
Heavy Atom Count 5 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 2
PubChem CID
441203
PubChem SID
134337530 , 137007875 , 137521154 , 139486572 , 14718343 , 160844883 , 160844890 , 17405476 , 175444044 , 175444045 , 249871544 , 252401149 , 36885096 , 57393766 , 74440810 , 7783791 , 8139843 , 8144441
ChEBI ID
ChEBI:27899
TTD Drug ID
D0U5HU
DT(s) Transporting This Drug ATP7B Transporter Info Copper-transporting ATPase 2 Substrate [2]
BCRP Transporter Info Breast cancer resistance protein Substrate [3]
COPT2 Transporter Info Probable low affinity copper uptake protein 2 Substrate [4]
CTR1 Transporter Info High affinity copper uptake protein 1 Substrate [5]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [6]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [7]
MRP6 Transporter Info Multidrug resistance-associated protein 6 Substrate [8]
OCT1 Transporter Info Organic cation transporter 1 Substrate [9]
OCT2 Transporter Info Organic cation transporter 2 Substrate [10]
P-GP Transporter Info P-glycoprotein 1 Substrate [11]
References
1 Cisplatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968.
3 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
4 Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66.
5 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
6 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
7 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
8 Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7.
9 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
10 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
11 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.